UK markets close in 7 hours 31 minutes
  • FTSE 100

    7,751.43
    -13.72 (-0.18%)
     
  • FTSE 250

    19,923.09
    -112.30 (-0.56%)
     
  • AIM

    868.57
    -0.67 (-0.08%)
     
  • GBP/EUR

    1.1374
    -0.0030 (-0.26%)
     
  • GBP/USD

    1.2373
    -0.0021 (-0.17%)
     
  • BTC-GBP

    19,044.65
    +225.29 (+1.20%)
     
  • CMC Crypto 200

    534.20
    +17.20 (+3.33%)
     
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • DOW

    33,978.08
    +28.68 (+0.08%)
     
  • CRUDE OIL

    78.93
    -0.75 (-0.94%)
     
  • GOLD FUTURES

    1,937.80
    -7.80 (-0.40%)
     
  • NIKKEI 225

    27,433.40
    +50.84 (+0.19%)
     
  • HANG SENG

    22,069.73
    -619.17 (-2.73%)
     
  • DAX

    15,114.57
    -35.46 (-0.23%)
     
  • CAC 40

    7,077.12
    -20.09 (-0.28%)
     

Medacta Group SA: First NextAR surgeries in Japan with the award-winning NextAR Augmented Reality Surgical Platform

Medacta Group SA / Key word(s): Market Launch
Medacta Group SA: First NextAR surgeries in Japan with the award-winning NextAR Augmented Reality Surgical Platform
10.01.2023 / 19:00 CET/CEST

 

MEDIA RELEASE

First NextAR surgeries in Japan with the award-winning NextAR Augmented Reality Surgical Platform

CASTEL SAN PIETRO, 10 January 2023Medacta is pleased to announce the first NextARTM surgeries have been successfully performed in Japan with its innovative NextAR, Augmented Reality Surgical Platform.  NextAR is the first surgical platform to offer personalized augmented reality solutions for both joint replacement and spine procedures leveraging patient-specific, unique real-time data to efficiently complement operative workflow.

Since the recent approval from Japanese Ministry of Health, Labour and Welfare (MHLW), NextAR Platform further enlarges its worldwide outreach, engaging with new surgeons with the aim of achieving better outcomes for patients.

  • NextAR Knee: “NextAR for TKA with GMK Sphere is one of the innovative enabling technologies in Computer Assisted Orthopedic Surgery which could deliver new surgical experience to Japanese surgeons in terms of augmented reality using smart glasses and CT-based ligament balance assessment and biomechanical simulation. Our group believes that it has the huge potential to improve patient outcomes. We are excited to provide new value for our patients,” Dr. Atsushi Sato, Ph.D.

  • NextAR Shoulder: Glenoid implantation is the crucial point of reverse shoulder arthroplasty. In cases with glenoid deformity, we were sometimes in trouble. NextAR Shoulder helps us to easily visualize the bony shape and precisely implant the glenoid component as we planned. I believe this new technology will lead to good clinical results for our patients,” says Dr. Noboru Matsumura.

  • NextAR Spine: NextAR setting up is very simple and navigation of the instruments is easy, with a smart tracking system of the instruments that drastically reduce the line of sight. What I really like about NextAR is the fast and simple procedure to getting started with spine navigation, combined to a very high level of accuracy of the screw placement thanks to the AR glasses” says Dr. Kanji Sasaki. “I think that NextAR combined with M.U.S.T. LT brings an innovative and efficient way to approach spine navigation, the array of navigable instruments is nice and very easy to set up, and the glasses allow me to maintain the focus on the surgical field while navigating the instruments. Accuracy is very impressive. NextAR is a very reliable system,” says Dr. Takeshi Umebayashi.

Through advanced 3D planning tools, a compact and revolutionary single-use tracking system, and augmented reality, NextAR enables data-driven decision-making allowing the surgeon to perform personalized procedures based on each patient's unique anatomy and biomechanics. These valuable insights are displayed through the NextAR Smart Glasses directly onto the operative field to give the surgeon enhanced visualization and control during the procedure. The increased level of data may provide more precision and could lead to improved patient outcomes.

“We are extremely proud that this unique, lean, and sustainable technology has reached a new relevant market, where it has sparked the interest of many surgeons. NextAR represents a new dimension for enabling technologies, seamlessly integrating into well-established surgical workflows,” says Francesco Siccardi, Chief Executive Officer of Medacta International.

In line with Medacta's philosophy of healthcare sustainability, the NextAR platform is offered as a hardware system with limited capital investment and single-use instrumentation at a low cost per case and offers the ability to host software for multiple applications. The platform represents an optimal solution worldwide, particularly for US Ambulatory Surgery Centers (ASCs).

The NextAR surgical platform is part of Medacta's MySolutions Personalized Ecosystem, an advanced network of digital solutions designed to improve patient outcomes and healthcare efficiency. MySolutions embodies Medacta's holistic approach to personalized medicine, aiming to bring value to every step of the patient journey from preoperative through postoperative care.

NextAR is also supported by the comprehensive, tailored educational offerings provided by the M.O.R.E. Institute. With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on spine procedures and products with personalized high-level educational pathways. With Medacta, the surgeon is never alone.

To learn more about NextAR Augmented Reality Surgical Platform please visit https://nextar.medacta.com/

 

Contact

Medacta International SA
Gianluca Olgiati     
Senior Director Global Marketing  
Phone: +41 91 696 60 60
media@medacta.ch

 

About Medacta

Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

Additional features:

File: First NextAR surgeries in Japan with the award-winning NextAR Augmented Reality Surgical Platform

End of Media Release

Language:

English

Company:

Medacta Group SA

Strada Regina

6874 Castel San Pietro

Switzerland

Phone:

+41 91 696 6060

E-mail:

info@medacta.ch

Internet:

www.medacta.com

ISIN:

CH0468525222

Listed:

SIX Swiss Exchange

EQS News ID:

1530459


 

End of News

EQS News Service

show this
show this